Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III long-term subcutaneous immunotherapy with TO-204 in HDM-sensitized allergic rhinitis and asthma
jRCT2080221855Phase 3
- Sponsor
- Torii Pharmaceutical
- Start
- Jul 2012
- Modality
- Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, single-arm trial of Der p Alutard SQ in allergic rhinitis (AR) and asthma, sponsored by Torii Pharmaceutical.
02
Drugs
Der p Alutard SQ
03
Conditions
allergic rhinitis (AR)asthma
Beyond the preview
Go deeper on jRCT2080221855.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221855.